Molecular Quality Controls Market: Notable Developments & Geographical Outlook
|
Attributes |
Details |
|
Molecular Quality Controls Market CAGR (2022 – 2032) |
7% |
|
Molecular Quality Controls Market (2026) |
US$ 226 Mn |
|
Molecular Quality Controls Market Attraction |
Asia Pacific to hold attractiveness |
The rising adoption of third-party quality controls,
the growing number of accredited clinical laboratories, the rising demand
for external quality assessment support, increasing government funding to
support genomics projects, increasing demand for personalized medicines,
declining sequencing costs, and the rising prevalence of infectious diseases,
cancer, and genetic diseases are all driving molecular quality controls
market forward.
The COVID-19 pandemic had a detrimental impact
on molecular quality controls sales. As governments increasingly loosen
their prohibitions on migration, there is a rise in testing numbers.
With the COVID-19 pandemic, dealing with infectious illness
has become a major medical concern throughout the world. There is an increasing
demand for more precise and easy testing methods, as well as the expansion
of testing structures. Companies have also made strategic decisions to
deploy COVID-19 quick testing, maintain revenue, and mitigate COVID-19's
influence on their operating capabilities.
Due to the expanding global burden of various diseases, the
number of laboratory tests performed has grown. The number
of laboratories in both the public and private sectors is growing to
satisfy this need.
Setting up a quality control process in a
clinical laboratory necessitates a large financial
commitment. Laboratories must also have specialized people to
supervise the quality control system.
Regardless of the number
of tests completed, QC procedures entail equal expenses. As
a result, the expense of implementing QC processes in
clinical laboratories that perform modest quantities
of diagnostic tests is prohibitively expensive. This, along with
funding restrictions in many hospitals and laboratories in both
developed and emerging economies, is projected to lead to a decreased adoption
of quality-control techniques.
New multi-analyte and multi-instrument controls have been
developed as a result of technological improvements. These cutting-edge
controls combine many instrument-specific controls into a single control,
allowing clinical laboratories to save money. In addition, these
controls save time by eliminating the need for separate QC processes for
each analyte.
In the next years, the increased availability of
such molecular quality controls for infectious
disease diagnostics and other applications is likely to
drive market expansion.
Key Takeaways:
- The
Asia Pacific molecular quality controls market is expected to
reach US$ 72.07 million in 2028 from US$ 34.27 million in 2021; it is
estimated to grow at a CAGR of 11.2%.
- The
European molecular quality controls market is expected to reach
US$ 109.59 million by 2028 from US$ 55.76 million in 2021; it is estimated
to grow at a CAGR of 10.1%.
- The
growing implementation of genomic sequencing in healthcare
systems is supported by substantial government investments, totaling
over US$ 4 billion by at least 14 countries.
Key Segments
By Analyte:
- Single-analyte
Controls
- Multi-analyte
Controls
By Product Type:
- Independent
controls
- Instrument-specific
controls
By Application:
- Infectious
Diseases Diagnostics
- Oncology
Testing and Genetic testing
By End User:
- Diagnostic
laboratories
- Hospitals
- IVD
manufacturer & CROs
- Academic
& Research Institutes
Browse
More@ https://www.futuremarketinsights.com/reports/molecular-quality-controls-market
Comments
Post a Comment